Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan D White

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery of [1,2,4]Triazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse AgonistsRyota Nakajima, Hiroyuki Oono, Sakae Sugiyama, et al.
Journal of Medicinal Chemistry|November 13, 2014
Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitorsOleg Epstein, Marian C Bryan, Alan C Cheng, et al.
Journal of Medicinal Chemistry|August 6, 2008
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonistsYuan Cheng, Brian K Albrecht, James Brown, et al.
ACS Medicinal Chemistry Letters|February 21, 2015
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular LiabilitiesYuan Cheng, James Brown, Ted C Judd, et al.
Journal of Medicinal Chemistry|March 8, 2008
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluationJean-Christophe Harmange, Matthew M Weiss, Julie Germain, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2015
Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's diseaseJian Jeffrey Chen, Qingyian Liu, Chester Yuan, et al.
Journal of Medicinal Chemistry|August 4, 2006
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Cell|April 23, 2024
DrugMap: A quantitative pan-cancer analysis of cysteine ligandabilityMariko Takahashi, Harrison B Chong, Siwen Zhang, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery of [1,2,4]Triazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse AgonistsRyota Nakajima, Hiroyuki Oono, Sakae Sugiyama, et al.
Journal of Medicinal Chemistry|November 13, 2014
Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitorsOleg Epstein, Marian C Bryan, Alan C Cheng, et al.
Journal of Medicinal Chemistry|August 6, 2008
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonistsYuan Cheng, Brian K Albrecht, James Brown, et al.
ACS Medicinal Chemistry Letters|February 21, 2015
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular LiabilitiesYuan Cheng, James Brown, Ted C Judd, et al.
Journal of Medicinal Chemistry|March 8, 2008
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluationJean-Christophe Harmange, Matthew M Weiss, Julie Germain, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2015
Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's diseaseJian Jeffrey Chen, Qingyian Liu, Chester Yuan, et al.
Journal of Medicinal Chemistry|August 4, 2006
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Cell|April 23, 2024
DrugMap: A quantitative pan-cancer analysis of cysteine ligandabilityMariko Takahashi, Harrison B Chong, Siwen Zhang, et al.
Pageof 3